| 000 | 01753 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514161051.0 | ||
| 264 | 0 | _c20031212 | |
| 008 | 200312s 0 0 eng d | ||
| 022 | _a0270-9139 | ||
| 024 | 7 |
_a10.1053/jhep.2003.50479 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPérez, María José | |
| 245 | 0 | 0 |
_aAdenovirus-mediated expression of Cu/Zn- or Mn-superoxide dismutase protects against CYP2E1-dependent toxicity. _h[electronic resource] |
| 260 |
_bHepatology (Baltimore, Md.) _cNov 2003 |
||
| 300 |
_a1146-58 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAdenoviridae _xgenetics |
| 650 | 0 | 4 |
_aAntioxidants _xmetabolism |
| 650 | 0 | 4 |
_aArachidonic Acid _xpharmacology |
| 650 | 0 | 4 |
_aButhionine Sulfoximine _xpharmacology |
| 650 | 0 | 4 |
_aCatalase _xgenetics |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2E1 _xmetabolism |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2E1 Inhibitors |
| 650 | 0 | 4 |
_aCytosol _xmetabolism |
| 650 | 0 | 4 |
_aCytotoxins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aFerric Compounds _xpharmacology |
| 650 | 0 | 4 | _aGene Transfer Techniques |
| 650 | 0 | 4 | _aGenetic Vectors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLipid Peroxidation _xdrug effects |
| 650 | 0 | 4 |
_aMembrane Potentials _xdrug effects |
| 650 | 0 | 4 |
_aMitochondria _xmetabolism |
| 650 | 0 | 4 |
_aNitrilotriacetic Acid _xanalogs & derivatives |
| 650 | 0 | 4 |
_aReactive Oxygen Species _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSuperoxide Dismutase _xphysiology |
| 700 | 1 | _aCederbaum, Arthur I | |
| 773 | 0 |
_tHepatology (Baltimore, Md.) _gvol. 38 _gno. 5 _gp. 1146-58 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1053/jhep.2003.50479 _zAvailable from publisher's website |
| 999 |
_c14320650 _d14320650 |
||